Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2020

Perfluorocarbon Liquids: Pearls and Pitfalls

Show Description +

Carl Regillo, MD, reviews the pros and cons of using perfluorocarbon liquids for both primary and complicated retinal detachments and explains how, although it can be used to ensure the best possible macular anatomy and visual outcomes, use of perfluorocarbon liquids still carries the risk of retention under the macula.

Posted: 3/24/2020

Up Next


Subretinal Gene Therapy

Christina Weng, MD, MBA, Timothy Murray, MD, MBA

Founders Lecture: Intraocular Sustained Drug Delivery

Glenn Jaffe, MD, Timothy Murray, MD, MBA

Neuroprotection for the Treatment of the Retina

Baruch Kuppermann, MD, PhD, Timothy Murray, MD, MBA

Best Approaches for Pediatric RD

Phil Ferrone, MD, Timothy Murray, MD, MBA

Perfluorocarbon Liquids: Pearls and Pitfalls

Carl Regillo, MD, reviews the pros and cons of using perfluorocarbon liquids for both primary and complicated retinal detachments and explains how, although it can be used to ensure the best possible macular anatomy and visual outcomes, use of perfluorocarbon liquids still carries the risk of retention under the macula.

Posted: 3/24/2020


Please log in to leave a comment.

Comments

Ramana Moorthy

4 years ago

1. Use of PFO/PFDs is a significant operative expense line item in the outpatient surgery center setting. So I would use it jusdiciously exactly as Dr. Regillo pointed out. 2. Recent popularity of PFO/PFD use for temporary (extended up to 10-14 days max) tamponade for complex inferior RD with PVR and recalcitrant macular holes must be weighed against post operative risks such as intraocular inflammation, toxicity to intraocular tissues, added surgical costs, time , and valuable OR resources (with repeat PPV for removal), and most importantly patient safety 3. There is still the need to have a non-toxic , non inflammatory alternative to perfluorocarbon liquids with similar optical and density characteristics. If developed this would be a game changer in VR surgery

More From ARDS: 2020 Coverage

Founders Lecture: Intraocular Sustained Drug Delivery

Glenn Jaffe, MD, Timothy Murray, MD, MBA

Neuroprotection for the Treatment of the Retina

Baruch Kuppermann, MD, PhD, Timothy Murray, MD, MBA